Clinical trials: Dose Finding Study
Cystitis, Interstitial, Urinary Bladder Disease
A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)
In this study several dose levels of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of female patients with Bladder Pain Syndrome / Interstitial Cystitis.
- Conditions
- Cystitis, Interstitial, Urinary Bladder Disease, Pain, Urologic Diseases
- Trial name
- AMARANTH (NCT01613586)
- Testing
- ASP3652
- Where
- 60 sites in Belgium, Czechia and 10 more
- Volunteers
- 287 people
- Sponsor
- Astellas Pharma Europe B.V.
Advanced Solid Tumors
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab.
- Trial name
- NCT04095273
- Testing
- Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 56 people
- Sponsor
- Bayer
Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
The goal of this clinical trial is to evaluate the safety and tolerability of the study drug WTX-330 when administered using a fixed dose regimen or a step-up dose regimen in adult patients with selected advanced or metastatic…
- Trial name
- NCT06939283
- Testing
- WTX-330
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Werewolf Therapeutics, Inc.
Multiple Myeloma
Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma
The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.
- Trial name
- NCT00231166
- Testing
- HCD122
- Where
- 7 sites in United States, Australia
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension
- Trial name
- NCT02129673
- Testing
- VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- ViSci Ltd.
Hypertension, Essential
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
The purpose of this study is to determine the blood pressure lowering responses of various dose combinations of nifedipine GITS and candesartan as compared to treatment with each component on their own (monotherapy) and placebo…
- Trial name
- DISTINCT (NCT01303783)
- Testing
- Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg
- Where
- 157 sites in United States, Argentina and 11 more
- Volunteers
- 1,381 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 in combination with Metformin in patients with type 2 diabetes for 24 weeks administration and to evaluate the safety and efficacy of MP-513 in…
- Trial name
- NCT00971243
- Testing
- MP-513 Lowest Dose and Metformin, MP-513 Low Dose and Metformin, MP-513 Medium Dose and Metformin
- Where
- 44 sites in Denmark, Germany and 5 more
- Volunteers
- 448 people
- Sponsor
- Tanabe Pharma Corporation
Neoplasms, Metastatic Cancer
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
- Conditions
- Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor
- Trial name
- NCT03307785
- Testing
- Niraparib, TSR-042, Carboplatin-Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Tesaro, Inc.
Idiopathic Restless Leg Syndrome
Rotigotine Restless Legs Syndrome Dose Finding Trial
The objective of this trial is to demonstrate clinical efficacy of four different dosages of SPM 962 1.125 mg, 2.25 mg, 4.5 mg and 6.75 mg (corresponding to 2.5 cm2, 5 cm2, 10 cm2 and 15 cm2 patch size respectively) in RLS…
- Trial name
- NCT00243217
- Testing
- SPM 936
- Where
- Germany
- Volunteers
- 341 people
- Sponsor
- UCB Pharma
Chemotherapy-induced Neutropenia
Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia
Randomized, Open-Label study to determine the dose, efficacy, safety and pharmacokinetic profile of ANF-RHO™ with once-per-cycle injection in comparison with Neulasta in Breast Cancer patients at high risk of developing…
- Trial name
- NCT03559387
- Testing
- ANF-RHO™, Neulasta®
- Where
- 8 sites in France, Netherlands
- Volunteers
- 9 people
- Sponsor
- Prolong Pharmaceuticals
Asthma
Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)
The aim of the study is to compare the efficacy of two doses of a fixed combination of ciclesonide/formoterol fumarate versus ciclesonide alone versus formoterol fumarate alone in patients with asthma.
- Trial name
- NCT00314509
- Testing
- Ciclesonide/Formoterol Combination
- Where
- 26 sites in France, Germany and 2 more
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Dyslipidemia, Hypercholesterolemia
A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study in Japanese patients to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy.
- Conditions
- Dyslipidemia, Hypercholesterolemia, High Cholesterol
- Trial name
- NCT05421078
- Testing
- Obicetrapib
- Where
- 10 sites in Japan
- Volunteers
- 102 people
- Sponsor
- NewAmsterdam Pharma
Gastrointestinal Endoscopy, Gastrointestinal Polypectomy
Dose Rate Range Finding Study of Propofol for minimal-to Moderate Sedation on Upper & Lower Endoscopic Tests
Phase IIB study to find the optimal dose rate range of propofol to maintain minimal-to-moderate sedation for diagnostic gastrointestinal endoscopy and gastrointestinal polypectomy.
- Trial name
- NCT01189604
- Testing
- ICI35,868 (propofol)
- Where
- 2 sites in Japan
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Asthma
A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma
The study is aimed at evaluating efficacy and safety of oglemilast in the treatment of stable mild to moderate persistent asthma. The study involves two weeks of run in period. This is a placebo controlled study.
- Trial name
- NCT00859404
- Testing
- oglemilast
- Where
- India
- Volunteers
- 282 people
- Sponsor
- Glenmark Pharmaceuticals Europe Ltd. (R&D)
Relapsing-remitting Multiple Sclerosis
Dose-finding Study of MT-1303
The primary objectives of the study are: To evaluate the effects of three oral doses of MT-1303 compared to placebo given for a period of 24 weeks in subjects with relapsing-remitting multiple sclerosis (RRMS) on MRI parameters…
- Trial name
- NCT01742052
- Testing
- MT-1303-Low, MT-1303-Middle, MT-1303-High
- Where
- 18 sites in Belgium, Bulgaria and 16 more
- Volunteers
- 415 people
- Sponsor
- Tanabe Pharma Corporation
Pneumococcal Vaccines
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 4 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving…
- Trial name
- NCT06720038
- Testing
- 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Narcolepsy Type 2
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Narcolepsy without cataplexy or Narcolepsy Type 2 (NT2) is a lifelong condition that makes people very sleepy during the day, regardless of how much sleep they get at night.
- Trial name
- NCT06952699
- Testing
- TAK-360
- Where
- 52 sites in United States, China and 5 more
- Volunteers
- 88 people
- Sponsor
- Takeda
Rheumatoid Arthritis
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
The study is conducted in order to find out if repeated doses of the monoclonal (artificially manufactured) antibody BT061 can help arthritis patients whose disease does not sufficiently respond to a treatment with methotrexate…
- Trial name
- NCT01481493
- Testing
- BT061
- Where
- 39 sites in Czechia, Germany and 5 more
- Volunteers
- 127 people
- Sponsor
- Biotest
Allergic Rhinitis
OC000459 Dose Finding Study in Hay Fever Sufferers.
The primary objective of this study is to evaluate a range of dose levels for efficacy in the control of symptoms of allergic rhinitis
- Trial name
- NCT00697281
- Testing
- OC000459
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Oxagen Ltd
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
The purpose of this study is to assess safety, tolerability and demonstrate a dose response signal using Total Symptom Score (TSS), based on challenges with grass pollen in an Environmental Exposure Chamber (EEC), followed by…
- Trial name
- NCT02556801
- Testing
- SUBLIVAC FIX Phleum Prat.
- Where
- Canada
- Volunteers
- 168 people
- Sponsor
- HAL Allergy
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.